Kemwell Biopharma Supplies Biologics Drug Substance For Phase l Clinical Trials For U.S. IND Filing
BANGALORE, India, May 17, 2017 /PRNewswire/ -- Kemwell Biopharma, a contract development and manufacturing service provider, announced today that it has manufactured and supplied drug substance using its state-of-the-art mammalian cell culture plant in India for clinical trials that will be performed by its customer in USA for an IND filing. The customer has received IND approval and is commencing Phase 1 clinical trials.
Kemwell provided a fully integrated solution including technology transfer, process optimization, scale-up, manufacturing of toxicology materials and cGMP manufacturing of drug substance clinical materials.
"Partnering with a number of well-known technology providers, Kemwell aims to establish itself as a leading player in the one-stop-shop biopharmaceutical contract manufacturing space. Our endeavor is to capitalize on the eastern advantage of a cost-friendly environment while offering all the western advantages of quality and innovation. As pharmaceutical companies are now concentrating their R&D budgets on large molecule products, we are seeing increased demand in our biotech services," says Kemwell's Managing Director, Anurag Bagaria.
Kemwell now has a strong team with senior scientists trained in USA and in-depth knowledge and technical expertise on development of new biological entities (NBE's), biosimilars and bio-betters. Their biotechnology capabilities include process development and manufacturing of drug substances and drug products for toxicology in 80L scale bioreactors, as well as for cGMP clinical and commercial manufacturing in 400L and 2000L bioreactors with corresponding downstream processing, fill & finish in liquid and lyophilized vials and integrated quality management.
Kemwell Biopharma Pvt Ltd is located in Bangalore, India and is a pure play contract development and manufacturing service provider for biopharmaceuticals. Kemwell's state-of-the-art facility is one of the largest available capacities for contract manufacturing of monoclonal antibodies and protein therapeutics derived from mammalian cell culture in India.
Read more about Kemwell on www.kemwellbiopharma.com
Name: Karan Bagaria
Contact: +91-80-39285450
Email: 160183@email4pr.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kemwell-biopharma-supplies-biologics-drug-substance-for-phase-1-clinical-trials-for-us-ind-filing-300459041.html
SOURCE Kemwell Biopharma
